Metraipolis › archive › dc_ea8a6f961872

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes — Europe PMC PMID:41716394

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41716394
DOI
10.3389/fimmu.2026.1776180
License (as archived)
solo-consultazione
Archived
2026-11-06T03:14:05.514Z
SHA-256 of the archived text
ef1e7886ba0589124a83ba37382f3fb08039f7acb472a131b251b696ab22319e
Stable URL of this page
https://metraipolis.com/documento/dc_ea8a6f961872

How to cite

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes — Europe PMC PMID:41716394 — Europe PMC (en), https://europepmc.org/article/MED/41716394 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ea8a6f961872 (Metraipolis archive dc_ea8a6f961872, sha256 ef1e7886ba0589124a83ba37382f3fb08039f7acb472a131b251b696ab22319e)
BibTeX
@misc{dcea8a6f961872,
  title = {Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes — Europe PMC PMID:41716394},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41716394},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ea8a6f961872; sha256 ef1e7886ba0589124a83ba37382f3fb08039f7acb472a131b251b696ab22319e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41716394. Agents can read the archived copy with the MCP tool read_document.